Albert Cha

TRIA Beauty, Inc. provides light based therapeutic beauty devices. It offers TRIA Laser Hair Removal System for laser removal of hair and TRIA Skin Perfecting Blue Light for mild to moderate inflammatory acne with a proprietary cleanser and serum for overall complexion improvement. The company was founded in 2003 by Tobin C. Island, Robert E. Grove, Jonathon T. Pearson and Mark V. Weckwerth and is headquartered in Dublin, CA.

Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada.

Biodel, Inc. is a pharmaceutical company, which develops novel formulations of already approved therapeutics to treat endocrine disorders such as diabetes and osteoporosis. The company develops product candidates by applying formulation technologies to existing drugs in order to improve their therapeutic profiles. Biodel was founded by Solomon S. Steiner and Erik Steiner on December 3, 2003 and is headquartered in Danbury, CT.

BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA.

Carbylan Therapeutics, Inc. engages in the development and market of medical devices and drug combination products to treat the pain associated with osteoarthritis. It offers Hydros Joint Therapy and Hydros-TA Joint Therapy, viscoelastic hyaluronan-based products designed to provide long term relief of the pain associated with osteoarthritis using a single intra-articular injection. The company was founded by Richard R. Orlandi, Albert Park, Glenn D. Prestwich and Richard K. Koehn in March 2004 and is headquartered in Palo Alto, CA.

Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA.

APT Pharmaceuticals, Inc. operated as a drug development company. The company was founded on December 15, 1999 and was headquartered in Burlingame, CA.

AirXpanders, Inc. engaged in the design, manufacture, sale and distribution of medical devices. It offers AeroForm Tissue Expander System, a needle-free, patient-controlled tissue expander used in patients undergoing two-stage breast reconstruction following mastectomy prior to the insertion of a breast implant. The company was founded by Daniel I. Jacobs, Barry Cheskin, and Teddy Shalon on March 17, 2005 and was headquartered in San Jose, CA.

NextWave Pharmaceuticals, Inc. operates as a pharmaceutical company which focuses on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder. The company was founded by Mahendra G. Shah on September 25, 2006 and is headquartered in New York, NY.

Vicept Therapeutics Inc. develops dermatologic therapeutic products. The firm develops topical agents for the treatment and prevention of a number of medical and cosmetic indications including bruising of the skin. The company was founded on July 1, 2009 by Neal Walker, Stewart D. Shanler, and Christopher V. Powala and is headquartered in Malvern, PA.

Health360, Inc. provides health services. Their pharmacists and health care professionals are dedicated to assisting you in the development and maintenance of a healthy lifestyle. The company is headquartered in Dublin, CA.

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA.

Neomend, Inc. develops surgical wound healing products. It offers adhesion prevention products for hospitals and medical facilities. The company was founded in 1999 and is headquartered in Irvine, CA.

Essentialis, Inc. develops therapeutic products in curing metabolic diseases. It operates as a pharmaceutical company focusing on the development of breakthrough medicines for the treatment of rare metabolic diseases where there is mortality and risk of cardiovascular and endocrine complications. The company was founded by Neil M. Cowen, Jeffrey A. Staffa and Thomas A. Glaze in 2004 and is headquartered in San Diego, CA.

KalVista Pharmaceuticals Ltd. develops novel plasma kallikrein inhibitors. It also engages in the development of serine protease inhibitors and novel plasma kallikrein inhibitors represent a, approach to the treatment of DME, a leading cause of adult visual loss, plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option. The firm has a clinical and advanced pre-clinical product pipeline targeting both intravitreal injection and oral administration, and its plasma kallikrein inhibitors can be applied to additional indications in ophthalmology. The company was founded by Lloyd Paul Aiello, Andrew Crockett, Robert Haigh and Edward P. Feener in 2011 and is headquartered in Porton Down, the United Kingdom.

Medley Health, Inc. was provided marketing and communications services. The company was founded by Jeni Waters, Kevin J. Appelbaum and Steven J. Wigginton in 2010 and was headquartered in Dublin, CA.

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Frazier Life Sciences Management LP (Frazier Life Sciences) is a private investment manager headquartered in Menlo Park, California. The firm was founded in 2021 as a newly spun off company from Frazier Management LLC. They are principally owned by Jamie Topper and Patrick Heron. Frazier Life Sciences provides discretionary investment management services to US private investment funds, Frazier Life Sciences Funds.